Company profile
Adaptam Therapeutics
Pioneering cancer immunotherapies targeting the immunosuppressive tumor microenvironment.
- Industry
- Biotechnology Research
- Employees
- 6
- Headquarters
- San Sebastián, Basque Country
- LinkedIn followers
- 662
- Office locations
- 1
Adaptam Therapeutics company summary
Adaptam Therapeutics is a company in the Biotechnology Research industry, headquartered in San Sebastián, Basque Country. On LinkedIn the company has around 6 employees and 662 followers.
What technology does Adaptam Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Adaptam Therapeutics
Adaptam Therapeutics is pioneering next-generation cancer immunotherapies by disrupting the immunosuppressive myeloid tumor microenvironment (TME) through glyco-immune checkpoints. The TME in solid tumors is enriched in immunosuppressive myeloid cells, such as tumor-associated macrophages (TAMs), which drive resistance or a lack of response to existing treatments. This remains one of the toughest challenges in cancer immunotherapy. Our discoveries in cancer immunology, T cell and myeloid cell biology have revealed previously unexplored cancer dependencies, demonstrating that specific glycan interactions with immune cells are key drivers of myeloid-mediated immune suppression. Adaptam is advancing a pipeline of first-in-class, antibody-based therapies targeting these central glycobiology pathways involved in myeloid immunosuppression. Our in-house antibody discovery expertise enables the development of antibody-drug conjugates (ADCs) and bispecific antibodies targeting the immunosuppressive TME. Focused on solid tumors, our programs are designed to transform cancer treatment across multiple indications by reprogramming the immunosuppressive tumor landscape while boosting T cell activity. A spin-off from CIC bioGUNE, Adaptam is supported by founding investor Criteria Bio Ventures and has secured competitive national and European funding, including several prestigious European Research Council (ERC) grants.
Where is Adaptam Therapeutics located?
Adaptam Therapeutics lists 1 location.
Compare companies similar to Adaptam Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Adaptam Therapeutics adaptamtx.com | Biotechnology Research | 6 | - | San Sebastián, Basque Country |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Adaptam Therapeutics
What does Adaptam Therapeutics do?
Adaptam Therapeutics is pioneering next-generation cancer immunotherapies by disrupting the immunosuppressive myeloid tumor microenvironment (TME) through glyco-immune checkpoints. The TME in solid tumors is enriched in immunosuppressive myeloid cells, such as tumor-associated macrophages (TAMs), which drive resistance or a lack of response to existing treatments. This remains one of the toughest challenges in cancer immunotherapy. Our discoveries in cancer immunology, T cell and myeloid cell biology have revealed previously unexplored cancer dependencies, demonstrating that specific glycan interactions with immune cells are key drivers of myeloid-mediated immune suppression. Adaptam is advancing a pipeline of first-in-class, antibody-based therapies targeting these central glycobiology pathways involved in myeloid immunosuppression. Our in-house antibody discovery expertise enables the development of antibody-drug conjugates (ADCs) and bispecific antibodies targeting the immunosuppressive TME. Focused on solid tumors, our programs are designed to transform cancer treatment across multiple indications by reprogramming the immunosuppressive tumor landscape while boosting T cell activity. A spin-off from CIC bioGUNE, Adaptam is supported by founding investor Criteria Bio Ventures and has secured competitive national and European funding, including several prestigious European Research Council (ERC) grants.
How many employees does Adaptam Therapeutics have?
Adaptam Therapeutics has around 6 employees on LinkedIn.
Where is Adaptam Therapeutics headquartered?
Adaptam Therapeutics is headquartered in San Sebastián, Basque Country.
Build a lead list from companies like Adaptam Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.